Anti-angiogenic drugs: from bench to clinical trials (Q36465476)

14 August 2017

1 reference

title

Anti-angiogenic drugs: from bench to clinical trials (English)

1 reference

14 August 2017

main subject

angiogenesis inhibitor

1 reference

Ana R Quesada

1

1 reference

14 August 2017

Ramón Muñoz-Chápuli

series ordinal

2

1 reference

14 August 2017

Miguel A Medina

series ordinal

3

1 reference

14 August 2017

publication date

1 July 2006

1 reference

Medicinal Research Reviews

14 August 2017

published in

1 reference

14 August 2017

volume

26

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

483-530

1 reference

Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane.

14 August 2017

cites work

1 reference

Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity

21 January 2018

1 reference

A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions

21 January 2018

1 reference

A phase I study of pentosan polysulfate sodium in patients with advanced malignancies

21 January 2018

1 reference

Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey.

21 January 2018

1 reference

Augmentation of antitumor effects of p53 gene therapy by combination with HDAC inhibitor

21 January 2018

1 reference

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

21 January 2018

1 reference

Radiation therapy and tamoxifen: concurrent or sequential? That is the question

21 January 2018

1 reference

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3).

21 January 2018

1 reference

Phase II trial of GM-CSF thalidomide in patients with androgen-independent metastatic prostate cancer

21 January 2018

1 reference

Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1.

21 January 2018

1 reference

A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium

21 January 2018

1 reference

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

VEGF-targeted therapy in metastatic renal cell carcinoma

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.1634/THEONCOLOGIST.10-3-191

Inhibition of angiogenesis by a new isocoumarin, NM-3

30 December 2023

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.52.426

Identifiers

DOI

10.1002/MED.20059

1 reference

14 August 2017

1 reference